In NSCLC, HER2 oncogenic amplification occurs in approximately 3% of cases without EGFR-TKI treatment and accounts for approximately 10% of cases with EGFR-TKI resistance [48]. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.